Hong Kong Stock Movement: GENOR-B Plummets 11.05%

Hong Kong Stock Movement GENOR-B fell 11.05%. According to recent important news: On September 3, GENOR-B issued 1.191 million new shares due to the exercise of stock options by the CEO and eligible employees, leading to stock price fluctuations. This move increased the number of shares in circulation, potentially raising investor concerns about equity dilution, resulting in a drop in stock price. Source: Zhitong Finance. The biopharmaceutical industry has recently experienced significant volatility. Stocks with High Trading Volume in the Industry Innovent Biologics fell 6.54%, with a transaction volume of HKD 1.967 billion. According to recent important news: On September 4, Innovent Biologics released its financial report for the first half of 2025, showing a year-on-year revenue growth of 50.6%, but the market is skeptical about its future profitability, leading to a decline in stock price. The company's gross margin increased to 86.8%, but selling expenses rose by 26.38% year-on-year. Source: Jinwu Finance. On September 2, Jefferies published a research report, raising the target price for Innovent Biologics to HKD 105 and maintaining a "Buy" rating, but the market remains cautious about its commercialization capabilities outside the oncology field. Source: Jefferies Research Report. On September 1, Innovent Biologics' stock price reached a 52-week high but subsequently fell back as investors remained cautious about the market performance of its new products. Source: Huigang Communications. The biopharmaceutical industry is experiencing increased volatility, and investment should be approached with caution. Kangfang Biotech fell 4.04%, with a transaction volume of HKD 1.872 billion. According to recent important news: On September 1, Citi raised the target price for Kangfang Biotech to HKD 177, maintaining an "Outperform" rating. Despite a 33.7% increase in sales, the net loss of RMB 570 million exceeded expectations, mainly due to one-time investment losses. On September 3, Jianyin International anticipated that Kangfang Biotech would release important clinical trial data at the World Lung Cancer Conference, emphasizing its leadership position in the PD-1/VEGF dual antibody market. On September 1, HSBC initiated coverage on Kangfang Biotech with a "Buy" rating and a target price of HKD 208, expecting a compound annual growth rate of over 50% in revenue from 2025 to 2027. Biotech stocks are performing strongly, attracting international attention. BeiGene fell 3.21%, with a transaction volume of HKD 1.387 billion. Based on recent important news: On September 2, Hillhouse Capital significantly reduced its holdings in BeiGene, cashing out over HKD 11 billion, leading to market concerns about the company's prospects and putting pressure on the stock price. On September 2, the company announced an abnormal trading fluctuation, indicating that uncertainties in the biopharmaceutical industry could affect the company's future performance, increasing market caution. On September 2, the company announced that its A-share stock had deviated by more than 30% over three consecutive trading days, raising market attention on stock price fluctuations. The biopharmaceutical industry has a long R&D cycle, high investment, and high risk